- Overview
- Data/Specifications
- Literature/Support
- How To Use
- Related Products
Overview
During differentiation of neural precursor cells, neurospheres downregulate Chondroitin sulfate proteoglycans (CSPGs). Proliferating neural precursors synthesize lecticans, including aggrecan, which are downregulated with differentiation; suggesting a link between CSPGs and CNS precursor biology.
Data/Specifications
Immunogen:ARGSV synthetic peptide conjugate. Clone: BC-3 Host: Mouse Myeloma: x63-Ag8.653 Isotype: IgG1 Light Chain type: kappa Specificity:Recognizes the aggrecanase (ADAMTS-1, -4 & -5)-generated N-terminal neoepitope ARG after cleavage between amino acids EGE and ARG within the interglobular domain of aggrecanase-catabolised aggrecan (Human aggrecan sequence enumeration). This antibody will not recognize the sequence ARG if it is in the non-cleaved intact aggrecan protein core; i.e. it will only recognize the aggrecanase generated neoepitope ARG. Cross-reactivity:human, rat, cat, cow, dog, guinea pig, horse, pig, rabbit and sheep. Purity: Affinity purified on protein G Form: Liquid, 1 mL/vial Concentration: 0.1 mg/mL Storage: -20° C |
Literature/Support
Aggrecan antibody, clone BC-3 Insert (PDF, 335 KB)
Joint Disease and Aggrecan (Blog Post)
How To Use
Applications
- Western Blot -Suggested dilution: 1:100.Detects a variety of epitopes between 50 and 250 kDa
- ELISA
- IHC with frozen sections or formalin/PFA-fixed paraffin embedded sections
Technical Notes
Samples must be deglycosylated using 0.01 Units Chondroitinase ABC (Sigma), 0.01 Units
Keratanase (Seikagaku) and 0.0001 Units Keratanase II (Seikagaku) per 10μg S-GAG of nondeglycosylated
aggrecan for optimal epitope recognition.
